ArticleCancers2020
Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Liquid Biopsy Revolutionizes the Precise Management of Tumors Across the Entire Course: Current Situation and Future Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Pooled it
- Exosome in Hashimoto's thyroiditis: from pathogenesis to diagnostic and therapeutic potential.Molecular biology reports · 2026Review
- Macrophage-induced immunomodulation in oral tissue repair and regeneration: Recent advances and future perspectives.Journal of advanced research · 2026Review
- Harnessing plasma transcriptomics for non-invasive cancer biomarker identification: a comprehensive review.Discover oncology · 2025Review
- Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2025Review
- Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA.Molecular oncology · 2025Article
- Potential utility of ADNP in circulating tumor cells as biomarker for prognostics in non-muscle-invasive bladder cancer.Scientific reports · 2024Article
- Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.International journal of molecular sciences · 2024Review
- A Comprehensive Review on Circulating cfRNA in Plasma: Implications for Disease Diagnosis and Beyond.Diagnostics (Basel, Switzerland) · 2024Review
- Review
- Decoding cell-type contributions to the cfRNA transcriptomic landscape of liver cancer.Human genomics · 2023Article
- Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC.Discover oncology · 2023Review
- Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.Clinical and translational medicine · 2022Article
- The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer.Thoracic cancer · 2022Article
- Exosome Processing and Characterization Approaches for Research and Technology Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less.Cancers · 2022Review
- Circulating non-coding RNAs as a diagnostic and management biomarker for breast cancer: current insights.Molecular biology reports · 2022Review
- UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better.United European gastroenterology journal · 2021Review
- Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy.Translational oncology · 2021Review
- Long Intergenic Non-Coding RNAs in HNSCC: From "Junk DNA" to Important Prognostic Factor.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Early detection of cancer holds high promise for reducing cancer-related mortality. Detection of circulating tumor-specific nucleic acids holds promise, but sensitivity and specificity issues remain with current technology. We studied cell-free RNA (cfRNA) in patients with non-small cell lung cancer (NSCLC; n = 56 stage IV, n = 39 stages I-III), pancreatic cancer (PDAC, n = 20 stage III), malignant melanoma (MM, n = 12 stage III-IV), urothelial bladder cancer (UBC, n = 22 stage II and IV), and 65 healthy controls by means of next generation sequencing (NGS) and real-time droplet digital PCR (RT-ddPCR). We identified 192 overlapping upregulated transcripts in NSCLC and PDAC by NGS, more than 90% of which were noncoding. Previously reported transcripts (e.g., HOTAIRM1) were identified. Plasma cfRNA transcript levels of POU6F2-AS2 discriminated NSCLC from healthy donors (AUC = 0.82 and 0.76 for stages IV and I-III, respectively) and significantly associated (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.